Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,802 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Detection of high-risk patients resistant to CDK4/6 inhibitors with hormone receptor-positive HER2-negative advanced and metastatic breast cancer in Japan (KBCSG-TR-1316).
Futamura M, Nakayama T, Yoshinami T, Oshiro C, Ishihara M, Morita M, Watanabe A, Tanigichi A, Tsukabe M, Shimoda M, Nitta K, Chihara Y, Yasojima H, Ouchi Y, Tokumaru Y, Masuda N. Futamura M, et al. Among authors: ishihara m. Breast Cancer. 2023 Nov;30(6):943-951. doi: 10.1007/s12282-023-01485-y. Epub 2023 Jul 24. Breast Cancer. 2023. PMID: 37486454 Free PMC article.
The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2018 edition.
Shimoi T, Nagai SE, Yoshinami T, Takahashi M, Arioka H, Ishihara M, Kikawa Y, Koizumi K, Kondo N, Sagara Y, Takada M, Takano T, Tsurutani J, Naito Y, Nakamura R, Hattori M, Hara F, Hayashi N, Mizuno T, Miyashita M, Yamashita N, Yamanaka T, Saji S, Iwata H, Toyama T. Shimoi T, et al. Among authors: ishihara m. Breast Cancer. 2020 May;27(3):322-331. doi: 10.1007/s12282-020-01085-0. Epub 2020 Apr 2. Breast Cancer. 2020. PMID: 32240526 Free PMC article.
Correction to: The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2018 edition.
Shimoi T, Nagai SE, Yoshinami T, Takahashi M, Arioka H, Ishihara M, Kikawa Y, Koizumi K, Kondo N, Sagara Y, Takada M, Takano T, Tsurutani J, Naito Y, Nakamura R, Hattori M, Hara F, Hayashi N, Mizuno T, Miyashita M, Yamashita N, Yamanaka T, Saji S, Iwata H, Toyama T. Shimoi T, et al. Among authors: ishihara m. Breast Cancer. 2021 Jul;28(4):985-986. doi: 10.1007/s12282-021-01252-x. Breast Cancer. 2021. PMID: 33886078 Free PMC article. No abstract available.
The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2022 edition.
Terada M, Ito A, Kikawa Y, Koizumi K, Naito Y, Shimoi T, Ishihara M, Yamanaka T, Ozaki Y, Hara F, Nakamura R, Hattori M, Miyashita M, Kondo N, Yoshinami T, Takada M, Matsumoto K, Narui K, Sasada S, Iwamoto T, Hosoda M, Takano Y, Oba T, Sakai H, Murakami A, Higuchi T, Tsuchida J, Tanabe Y, Shigechi T, Tokuda E, Harao M, Kashiwagi S, Mase J, Watanabe J, Nagai SE, Yamauchi C, Yamamoto Y, Iwata H, Saji S, Toyama T. Terada M, et al. Among authors: ishihara m. Breast Cancer. 2023 Nov;30(6):872-884. doi: 10.1007/s12282-023-01505-x. Epub 2023 Oct 7. Breast Cancer. 2023. PMID: 37804479 Free PMC article.
CD204-positive macrophages accumulate in breast cancer tumors with high levels of infiltrating lymphocytes and programmed death ligand-1 expression.
Nagano M, Saito K, Kozuka Y, Ichishi M, Yuasa H, Noro A, Imai N, Shibusawa M, Kimoto M, Ishitobi M, Tono Y, Oda H, Ishihara M, Mizuno T, Ogawa T, Katayama N. Nagano M, et al. Among authors: ishihara m. Oncol Lett. 2021 Jan;21(1):36. doi: 10.3892/ol.2020.12297. Epub 2020 Nov 12. Oncol Lett. 2021. PMID: 33262828 Free PMC article.
Pertuzumab, trastuzumab and eribulin mesylate therapy for previously treated advanced HER2-positive breast cancer: a feasibility study with analysis of biomarkers.
Tono Y, Ishihara M, Miyahara Y, Tamaru S, Oda H, Yamashita Y, Tawara I, Ikeda H, Shiku H, Mizuno T, Katayama N. Tono Y, et al. Among authors: ishihara m. Oncotarget. 2018 Feb 16;9(19):14909-14921. doi: 10.18632/oncotarget.24504. eCollection 2018 Mar 13. Oncotarget. 2018. PMID: 29599915 Free PMC article.
A phase 1 trial of NY-ESO-1-specific TCR-engineered T-cell therapy combined with a lymph node-targeting nanoparticulate peptide vaccine for the treatment of advanced soft tissue sarcoma.
Ishihara M, Nishida Y, Kitano S, Kawai A, Muraoka D, Momose F, Harada N, Miyahara Y, Seo N, Hattori H, Takada K, Emori M, Kakunaga S, Endo M, Matsumoto Y, Sasada T, Sato E, Yamada T, Matsumine A, Nagata Y, Watanabe T, Kageyama S, Shiku H. Ishihara M, et al. Int J Cancer. 2023 Jun 15;152(12):2554-2566. doi: 10.1002/ijc.34453. Epub 2023 Feb 17. Int J Cancer. 2023. PMID: 36727538 Clinical Trial.
1,802 results